SUDA Pharmaceuticals Ltd (SUDA), based in Australia and the US, is a world leader in reformulating and delivering medication through the oral mucosa.
Patients typically take medication as pills, tablets or capsules yet less than 25% of the medication is absorbed into the bloodstream.
SUDA can increase the bioavailability of administered medications, which means it increases the amount of the drug absorbed by the body so is able to increase the effect of that drug.
SUDA has increased bioavailability up to 95%. This is a major step forward in the evolution of drug delivery technology.
Latest Media Releases
Latest News
Company News /
by Lauren Evans -
A month ago
03 Sep 2021 - Suda Pharmaceuticals (ASX: SUD) has appointed Dr John Maher to its scientific advisory board for the iNKT cell therapy platform.
Interviews /
by Lauren Evans -
3 months ago
01 Jul 2021 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO & Managing Director Dr Michael Baker discusses the company's acquisition of the invariant natural killer T (iNKT) cell ther…
Company Presentations /
by -
10 months ago
24 Nov 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director and CEO Dr Michael Baker provides an overview of the company, discussing its OroMist technology, Zolpimist an…
Interviews /
by Rachael Jones -
10 months ago
24 Nov 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director Dr Michael Baker discusses the company's technology to convert solid dose drugs into oral sprays and the outl…
Market Reports /
by Katrina Bullock -
11 months ago
13 Nov 2020 - The SPI indicates that the Australian share market will open lower after the global vaccine rally teetered off bringing into sharp focus the latest wave of Covid-19 c…
Interviews /
by Katrina Bullock -
A year ago
13 Mar 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker talks 1H20 results progress with the company's lead product Zolpimist, the spay version of Sanofi’s block…
Interviews /
by Ortenzia Borre -
A year ago
08 Jan 2020 - SUDA Pharmaceuticals Limited (ASX:SUD) CEO, Dr Michael Baker, talks about the company’s plans to develop Anagrelide, for the treatment of cancer, and to commercialise…
Market Reports /
by Katrina Bullock -
A year ago
30 Dec 2019 - The SPI is pointing to a fall at the open, despite positive leads on Friday from the US. The Dow Jones Industrial Average and the broader S&P 500 edged to fresh recor…
Company Presentations /
by -
2 years ago
23 Sep 2019 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director and CEO, Stephen Carter presents on the company's portfolio and the benefits of reformulating and delivering …
Interviews /
by Anna Napoli -
2 years ago
23 Sep 2019 - SUDA Pharmaceuticals Limited (ASX:SUD) Managing Director & CEO, Stephen Carter discusses the company's portfolio and the benefits of reformulating and delivering medi…
Company Presentations /
by Carolyn Herbert -
5 years ago
13 Nov 2015 - Suda Limited, (ASX: SUD) Chief Business Officer, Nick Woolfe presents at the ASX Spotlight Series in Hong Kong. goes here
